Abstract The gene RAI was originally described as an inhibitor of RelA/p65 subunit of nuclear factor κB (NF-κB). Here, we analyse the association between genetic variation in the genes RAI and CD3EAP and outcome of 348 myeloma patients treated with high-dose treatment (HDT), 146 patients treated with interferon-α (INF-α) as maintenance treatment, 177 patients treated with thalidomide, and 74 patients treated with bortezomib at relapse and address if the effects of polymorphisms in CD3EAP and RAI are modified by a functional polymorphism in NFКB1. By linkage disequilibrium mapping, we found that variant alleles of several polymorphisms in a sub-region of 19q13.3 spanning the regions RAI-intron1-1 to RAI intron1-3 and the region exon1 to exon3-6 in CD3EAP were associated with prolonged time-to-treatment failure (TTF; p=0.003) and overall survival (OS; p=0.02 -010-1105-z analyses revealed that none of the haplotypes were more strongly associated to TTF or OS than the two strongly linked SNPs, RAI-intron1-1 (rs4572514) and CD3EAP G-21A (rs967591). The association of RAI-intron1-1 and CD3EAP G-21A with TTF was independent of NFKB1-94 ins/del, but homozygous ins-allele carriers which were also variant allele carriers of RAI-intron1-1 or CD3EAP G-21A had the longest OS. Among patients treated with INF-α or thalidomide, no effect was seen in relation to genotype. Our results indicate that polymorphism in RAI and CD3EAP are associated with outcome of myeloma patients treated with HDT. Combination analyses with the functional polymorphism in NFKB1 suggest that a possibly functional effect of RAI or CD3EAP could be related to NF-κB availability.
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Introduction
Multiple myeloma (MM) is an incurable B cell malignancy. Younger patients are treated with high-dose treatment (HDT) and stem cell support. Despite this intensive treatment strategy, a huge variation in treatment outcome is seen, with some patients suffering from early and aggressive recurrence of the disease. Understanding the mechanism of these differences may help us to establish new and better treatment strategies. Response to chemotherapy may reflect the effect of genetic variation related to differences in DNA repair, apoptosis and immune response.
A small region on the human chromosome 19q13.3 may be important for the development of cancers of the breast, lung and skin as well as outcome of chemotherapy ( Fig. 1 ) [1] [2] [3] [4] . The region encompasses four genes. Two genes, related to NER, the excision-repair cross-complementing 1 (ERCC1) and ERCC2 (XPD), are involved in repair of bulky DNA damage caused by chemotherapy [5] . The gene product of the third gene RAI (RelA inhibitor; also named iASPP or protein phosphatase 1, regulatory (inhibitor) subunit 13 like (PPP1R13L)) [6, 7] was identified as a protein that binds to the NF-κB subunit p65/RelA and inhibits its transcriptional activity [8] . The inhibition of NF-κB transcription induced apoptosis [8] . Later studies revealed that the RAI protein also inhibits apoptosis by binding to p53 [9] . Recently, over-expression of RAI has been shown to increase tumour formation in primary mouse embryonic fibroblasts [7] . These data support the hypothesis that RAI may function as an oncogene. The fourth gene in the chromosome region 19q13.3 is named CD3EAP (CD3e molecule epsilon-associated protein, alias ASE1 (anti-sense to ERCC1); alias CAST)) [5] . The gene was cloned by use of autoimmune serum from a patient with interstitial cystitis [10] . It is orientated anti-sense to and overlaps with the ERCC1 gene, and it has therefore been suggested that the mRNA of CD3EAP may bind the transcript of ERCC1 and inhibit translation [11] . This hypothesis was not supported by scientific results. The protein is localised in the fibrillar centres of the nucleus, which may indicate a function in ribosomal RNA transcription [11] . Another study by Yamazaki et al. suggests that the gene product of CD3EAP mediates activation signals, important for IL-2 production [12] . In a recent study of 59 NCI60 human tumour cell lines, sensitivity to anticancer drugs correlated positively with the variant A-allele of the polymorphism CD3EAP G-21A [13] . At present, the function of the gene is not clearly established. We have earlier shown that genetic variation in CD3EAP is associated with outcome in patients with multiple myeloma treated with HDT [4] . Patients carrying the variant A-allele of CD3EAP G-21A had a significant longer TTF and overall survival
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Chromosome sub-region 19q13. 3 Fig . 1 Schematic presentation of the sub-region 19q13.3 investigated in the current study (OS) after HDT [4] . These results support the notion that the genomic region influence outcome of chemotherapy. The gene NFКB1 encodes the p50 subunit and its precursor p105. We have previously shown that the polymorphism NFКB1-94 ins/del is associated with outcome of interferon-α (INF-α) maintenance treatment after HDT in patients with MM [14] .
The aim of the present study was to gain further knowledge of impact of genetic variation in the human chromosome region 19q13.3, by fine-mapping associations between many single-nucleotide polymorphisms (SNPs) with outcome of 348 myeloma patients treated with HDT. Furthermore, we analysed if genes in the chromosome subregion19q13.3 interplay with the polymorphism in NFКB1 in relation to outcome of multiple myeloma treated with HDT and maintenance treatment with interferon-α.
Materials and methods
Subjects, clinical data, response criteria, eligibility criteria and treatment for patients included in SNP analysis Subjects, clinical data, response criteria and eligibility criteria have previously been described in detail [4, 14, 15] . Briefly, patients diagnosed with MM and treated with HDT and stem cell support from August 1994 to August 2004 were recruited from four participating centres in Denmark. Three hundred forty-eight patients were included in the study. Staging was according to Durie and Salmon and the International Staging System (ISS). Time-totreatment failure (TTF) and OS were calculated from date of stem cell infusion to date of progression or death. Progression was defined by a more than 25% increase in serum M-protein or 25% increase in immunoglobulin levels above upper normal levels, confirmed by two separate measurements within a 1-month interval. Increase in bone marrow infiltration of plasma cells by 25% and increase of Bence-Jones proteinuria to more than 1.0 g/24 h or other signs of progression such as hypercalcaemia, progressive skeletal disease or soft-tissue plasmacytoma were also considered as progression. The occurrence of other malignancies and death without progression was regarded as events not related to progression. These patients were included in the analysis of OS, but they were excluded at time of death in the analysis of TTF. Complete response after HDT was defined by the disappearance of M-proteinform serum and urine, as detected by agarose gel electrophoresis and less than 5% plasma cells in the bone marrow aspirate. Partial response was defined by a reduction of at least 50% in the initial serum M-protein concentration and a reduction of light-chain proteinuria to less than 0.2 g/24 h. Time-to-next treatment (TNT) was used as follow-up after relapse treatment and was defined as the period from start of relapse treatment to start of new relapse treatment, progression without new treatment or death.
Induction therapy was three-series VAD (vincristine, doxorubicin and dexamethasone) or two to three series of cyclophosphamide 1 g/m 2 iv on day 1 combined with dexamethasone 40 mg daily po, on days 1-4 and days 9-11 (total dose, 320 mg for each series) repeated every 3 weeks. Peripheral blood stem cells were harvested at regeneration after cyclophosphamide priming, and the patients thereafter underwent high-dose chemotherapy with melphalan (200 mg/m 2 ) followed by stem cell support. Fifty-three patients received a second HDT upfront. Maintenance therapy with IFN-α was implemented 3 months after HDT according to standard treatment practise in the particular region (median 105 days) [14] . Two hundred and forty-three patients experienced relapse which required treatment. Among these patients, 177 were treated with thalidomide and 74 were treated with bortezomib [15] .
Peripheral blood mononuclear cells (PBMC's) was purified from 292 leukapheresis products by buffy coat preparation. From 56 patients, 10×10-μm sections were collected from paraffin-embedded bone marrow samples. Material was not available for 19 patients undergoing HDT, and these patients were not included in the study.
The study was approved by the Danish Ethical Committee (01-158/03).
DNA purification DNA for analysis was purified from PBMC by the salting out method [16] or from paraffin-embedded tissue by phenol extraction as described elsewhere [17] .
Genotyping of single-nucleotide polymorphisms
The XPD (ERCC2) SNP rs238406, rs238407, rs2097215, the RAI SNPs rs10422489, rs4544343, rs6966, rs12986272, rs10402584, rs10402393, rs4572514, rs4803816, rs95947, rs928911, rs4803817, nr.106, rs10412761 and the CD3EAP (ASE1) SNPs rs8113779, rs2013521, rs735482, rs762562, rs2336219, rs3212986, rs3212985, rs1007616 and the ERCC1 SNPs rs3212969, rs3212961, rs2298881 and rs1319052 were tested using a Sequenom® platform (San Diego, CA) and the iPLEX gold reaction. Each PCR reaction contained 10 ng of genomic DNA, 0.5 U HotStar Taq from Qiagen (Hilden, Germany), 1.25× Enzyme Buffer (Qiagen), 3.5 mM MgCl 2 and 1 mM of each deoxynucleotide. The primers were added to a final concentration of 500 nM each. The total reaction volume was 4-μl. PCR reactions with primers of each plex were performed in 384-well plates with V-shape by performing a 15-min preheat to 94 C followed by cycling the samples 45 times, 94 C for 20 s, 56 C for 30 s and 72 C for 1 min, followed by 3 min at 72 C. The plates were stored at −20 C. Treatment with Shrimp Alkaline Phosphatase and extension with molecular weight-modified nucleotides was performed according to the manufacturer's recommendations. The reactions were cleaned with resin and spotted on SpectroChip arrays according to the manufacturer's recommendations. The reactions were analysed by MALDITOF mass spectrometry on the Sequenom equipment, and the results were analysed using the MassARRAY Type 4.0 (Sequenom). The primers and probes are presented in supplement Table 1 . For XPD-exon23 (rs13181), XPDexon10 (rs1799793), RAI-intron8-1 (rs1970764), ASE1-exon1 (rs967591), ERCC1-exon4 (rs317770) and NFКB1 ATTG (rs28362491), the method has been previously reported [4, 14, 18] .
Statistical methods SPSS statistical software was used for all calculations (SPSS for Windows, Rel. 14.0.0. 2005, Chicago: SPSS Inc.). All tests were two-sided and P-values<0.05 were regarded as statistically significant. Fisher's exact test was used to compare categorical variables and the Mann-Whitney test was used to compare continuous and categorical variables. Kaplan-Meier method and the log rank test were used to compare TTF and OS between groups. The Cox proportional hazard model and log-likelihood statistics were applied for univariate analyses and covariates and for multivariate analysis.
Results
Study population
Three hundred and forty-eight myeloma patients were treated with HDT and stem cell support. The patient characteristics are presented in Table 1 . The median age of the patients was 56 years, and the study included 59% males. The median follow-up of all patients still alive was 93.4 months (range, 54.6-174.2 months). At follow-up, 208 patients had died. The median OS was 69.8 months (60.5-81.6 months). The median TTF was 27.7 months (23.4-30.8 months). One hundred and forty-six patients were treated with INF-α maintenance treatment.
The genotype frequencies of XPD, RAI, CD3EAP and ERCC1 and their influence on TTF, OS and response to treatment All genetic variation in the chromosomal region was previously identified by sequencing of breast cancer patients and healthy controls [19] . The genotype frequencies and association of minor allele frequency with TTF and OS after HDT are summarised in supplementary completeness of the investigation, we have also included previously reported SNPs in the region [4] . The percentage of successful genotype determinations was low for a number of polymorphisms, reflecting that the mass-spectrometrybased genotyping was unsuccessful for DNA isolated from paraffin-embedded tissues, which constituted 16% of the samples. The outcome for homozygous wild-type carriers versus variant carriers association of single polymorphisms in XPD, RAI, CD3EAP and ERCC1 is illustrated in Fig. 2 . A sub-region of 19q13.3 on the chromosome spanning the regions RAI-intron1-1 to RAI-intron1-3 and the region exon1 to exon3-6 in CD3EAP was significantly associated with TTF and OS in myeloma patients treated with HDT, and carriers of the variant allele of the SNPs had prolonged TTF and OS. There was no difference in the allele frequencies among patients dependent on the participating centres, and there was no difference in genotype distribution in relation to age, β2-mcroglobulin, creatinine, albumin, Durie-Salmon stage, ISS stage, gender, tandem HDT upfront, INF-α maintenance treatment, second HDT at relapse, treatment with thalidomide or bortezomib (supplementary Table 3 ). There was no association between allele frequencies and response to treatment.
Haplotype analysis of XPD, RAI, CD3EAP and ERCC1 and the influence on TTF and OS in myeloma patients treated with HDT Pair-wise linkage disequilibrium and block structure of 33 SNPs in the genes XPD, RAI, CD3EAP and ERCC1 using the haplo-view software programmes are illustrated in supplementary Figure 1 . Two haplotype analyses were generated for the sub-region 19q13.3. One haplotype analysis covered the genes RAI, CD3EAP and ERCC1 (rs4803816, rs967591, rs3212985 and rs1319052) and the other haplotype covered the gene CD3EAP (rs8113779, rs735482, rs3212986 and rs1007616). The two haplotype analyses included 97.6% and 85% of all patients with available genotype data in the study, respectively. None of the haplotype analyses revealed stronger association to TTF or OS than the two most significant SNPs, RAI-intron1-1 (rs4572514) and ASE1-exon1 (rs967591).
Combination of SNPs
Supplementary Table 4 and Fig. 3 show the combination analysis of NFKB1-94ins/del, CD3EAP G-21A and RAIintron1-1. When genotypes of CD3EAP or RAI were combined with genotypes of NFKB1-94ins/del, carriers of the variant A-allele of CD3EAP G-21A or the variant Callele of RAI-intron1-1, a prolonged TTF was seen independently of the NFKB1-94ins/del genotype, in contrast to OS, where an increase in median survival to more than 10 years, was seen only among carriers of the variants alleles of either CD3EAP G-21A or RAI-intron1-1, when combined with the wild-type ins-allele of NFKB1-94ins/del.
Analysis of the effect of genotypes on TTF and OS in patients treated with INF-α, thalidomide and bortezomib
TTF and OS were compared in groups subdivided by genotype and INF-α treatment. Among patients treated with INF-α, carriers of the variant C-allele or RAIintron1-1 had a significant prolonged TTF and OS (56.3 months and not reached, respectively) as compared with homozygous T-allele carriers (30.5 months and 74.4 months, respectively). However, when tested in a multivariate Cox analysis, the analysis showed that the difference in TTF was not related to treatment with INF-α and only a trend was found for OS (p = 0.06). No association between treatment outcome of thalidomide and bortezomib with genotype was found, except for carriers of the variant A-allele of CD3EAP G-21A, where significantly prolonged OS was seen among patients treated with bortezomib. We explored combination analyses of NFKB1-94ins/del, CD3EAP G-21A and RAI-intron1-1 in relation to treatment with INF-α and the results are shown in Table 2 .
Patients treated with INF-α, who carried two copies of the T-allele of RAI-intron1-1 and the variant del-allele of NFKB1-94ins/del had a significantly shorter TTF, and patients who carried the variant del-allele of NFKB1-94ins/del and either of the wild-type alleles of CD3EAP G-21A or RAIintron1-1 had a significant shorter OS survival as compared with carriers of the wild-type ins-allele of NFKB1-94ins/del in combination with the variant alleles of either CD3EAP G-21A or RAI-intron1-1 (Fig. 4) .
Discussion
We have explored a sub-region in 19q13.3 by finemapping associations between many single-nucleotide polymorphisms (SNPs) and treatment outcome in 348 myeloma patients treated with HDT. We found that several polymorphisms in a region spanning the genes RAI-intron1-1 and CD3EAP-exon3-6 were significantly associated with TTF and OS in myeloma patients. The effects of the polymorphisms RAI-intron1-1 and CD3EAP G-21A on gene functions are not known. Both SNPs are located in the 5′ region of their respective genes, the first intron and the 5'UTR, respectively, but none of them are located in the reading frame, and one may speculate that they affect transcription efficiency or gene regulation. In the studied population of patients, the effects of polymorphisms in RAI and CD3EAP were similar, and we found a pair-wise linkage disequilibrium between RAIintron1-1 (rs4572514) and CD3EAP G-21A (rs967591) of D´=0.94, suggesting that they detect the same biological effect. The gene RAI was initially identified as an inhibitor of the NF-κB subunit p65. The pro-inflammatory NF-κB consists of the dimer p50/p65. The NFКB1-94ins/del ATTG polymorphism is an insertion/deletion of four bases in the promoter region of the NFКB1 gene encoding both of the NF-κB transcription factors, p50 and p105. We therefore combined the polymorphism NFKB1-94ins/del with polymorphism in RAI-intron1-1 in relation to outcome of treatment. From previous results, we know that TTF and OS are not significantly affected by the polymorphism NFKB1-94ins/del [18] . The deletion produces lower transcripts levels in luciferase reporter systems and thus results in lower levels of NF-κB p50 [20] . In myeloma patients treated with HDT, the effect on TTF for the polymorphism RAI-intron1-1 was independent of the polymorphism NFKB1-94ins/del. Assuming that RAI is indeed an inhibitor of NF-kB p65, this would indicate that NF-κB p65 levels influence TTF and that this effect is independent from differences in NF-κB p50 levels. For OS, the effect of RAI-intron1-1 was in favour of patients also carrying the wild-type ins-allele of NFKB1-94ins/del, and these findings support that the classical NF-κB pathway (p65/p50 dimer) is involved in survival of myeloma patients after HDT.
In this population of patients, a subgroup of 146 patients was treated with INF-α as maintenance treatment after HDT. The decision of starting INF-α treatment was solely based on different treatment guidelines on starting post- HDT maintenance treatment at the participating departments and therefore not connected with selection bias. Interferon and NF-кB are central for the regulation of apoptosis, cell growth and for modulation of the immune system [21, 22] . From previous results, we know that the polymorphism NFKB1-94ins/del influences outcome for patients treated with INF-α as maintenance treatment [14] . Among patients treated with INF-α, carriers of the variant del-allele carriers of NFKB1-94ins/del and the wild-type Tallele of RAI-intron1-1 had a significant shorter TTF and OS survival as compared with double homozygous wildtype carriers. The effect of INF-α may therefore depend on a normal transcription level of the NF-κB p50 subunit and the availability of the p65 subunit of NF-κB for transcription activity. In the combination analyses, CD3EAP G-21A AG+GG was similar to RAI-intron1-1 TC+CC, probably due to their strong linkage (supplementary Figure 1) . In general, RAI-intron1-1 had the stronger effect, perhaps indicating that RAI-intron1-1 is the biologically relevant polymorphism. In carriers of the variant A-allele of CD3EAP-G-21A, a significantly prolonged OS was seen for patients treated with bortezomib. If true, this result could be interesting because Hideshima et al. recently found that bortezomib treatment increases NF-κB-dependent transcription in myeloma cells in vitro via activation of two upstream NF-κB-activating kinases, RIP2 and IККβ [23] . However, in our cohort of patients, only few patients were treated with bortezomib, and consequently, the statistical power to detect interaction with bortezomib was limited. No effect on TNT was seen, and combination analysis of RAIintron1-1 did not reveal the same statistically significant results ( Table 2) . We conclude that the polymorphisms RAI-intron1-1 and CD3EAP-exon3-6 are associated with outcome of myeloma patients treated with HDT. The effects of the polymorphisms on gene function are unknown, as well as the function of the genes RAI and in particular CD3EAP. The findings should be sought replicated in an independent study group of similarly treated multiple myeloma patients. Combination analyses with the functional polymorphism in NFKB1 suggest that a possibly functional effect of RAI or CD3EAP could be related to NF-κB availability. This hypothesis should be tested at the molecular level.
